Xiaolin Zhang, Dizal CEO

#ES­MO22: Dizal touts win in niche NSCLC pop­u­la­tion cor­nered by Take­da, J&J

As­traZeneca spin­out Dizal said its can­cer drug cleared the pri­ma­ry goal in a Phase II tri­al of pa­tients with EGFR ex­on 20 in­ser­tion mu­ta­tions, for which Take­da and J&J have ap­proved meds, and oth­ers like Cul­li­nan On­col­o­gy and Blue­print Med­i­cines are at­tempt­ing to treat.

Send­ing out the da­ta in the ear­ly hours of this year’s Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy meet­ing in Paris, Dizal said 59.8% of pa­tients evalu­able as of the end of Ju­ly had a con­firmed ob­jec­tive re­sponse. The study, con­duct­ed in Chi­na, test­ed the break­through-des­ig­nat­ed sun­voz­er­tinib in plat­inum-pre­treat­ed non-small cell lung can­cer pa­tients who have EGFR ex­on 20 in­ser­tion mu­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.